Why CEU's
Support where you need it
A self-governing body, the CSCT admits and revokes membership in the Society and encourages all members to maintain professional standards by participating in a Continuing Education Units (CEU) system. With technology advancing so rapidly, the CSCT is working to upgrade and maintain national professional standards in the field of Cardiac testing. Today we have over 2,000 Associate and Registered members in Canada.
CEU Information
What are CEU's and how many do I need?
Continuing Education Units (CEU) are collected and aid in members keeping in touch with the changing technologies occurring within our field. You need to collect 30 CEU's during each triennium. (each 3 year period)
Need Free CEU Opportunities?
There are a plethora of Free opportunities found here! Canadian Society of Cardiology Technologists - Educational Links (csct.ca) The OSCT website and Facebook page has continued to post opportunities, most of them free.
When do I submit my CEU's?
You may scan your CEU's and submit them to the CEU Director - ceu@osct.ca or you may submit them by mail whether you choose to all at once or as you collect them.
CEU SUBMISSION FORM
To download the CEU Submission form available on the OSCT website. All submissions must be accompanied by a completed CEU form.
PLEASE NOTE When submitting the Below CEU's:
If you have completed the maximum eight (8) 2F section credits Below, for the 2021 calendar year; you may submit a summary of at least 2 paragraphs, to earn 1 CEU per summary. *** When submitting any or all of the BELOW ACTIVITIES please note a summary only submission as "2F-SP21" on the form.
Free CEU Links
CEU Guidelines
Detail your services
Continuing Education Units (CEUs) are intended to broaden the knowledge base of the professional technologist. The CSCT and OSCT’s goal is to maintain a high standard of excellence and quality within our membership. The following CEU guidelines will help guide members in their endeavor to obtain CEUs. CEUs should be obtained from current sources and add to the basic knowledge members received during their schooling and subsequent employment, therefore CEUs must be above entry level to practice or “basic level” to earn units. Subject matter that a member is reasonably expected to have learned prior to writing the CSCT exam cannot be accepted as a continuing education unit i.e. Cardiac physiology, normal heart rhythms, etc. Below are some guidelines to support members in their endeavor to obtain CEUs. Advanced CEUs are routinely provided through both the OSCT and CSCT websites.
CEU Standards Guidelines
1. Only CEUs accumulated and submitted during the current triennium will be accepted.
2. Documentation or proof of attendance must accompany all CEU submissions. Members are responsible for keeping originals of all documentation in case of a discrepancy. CEU coordinators may or may not keep copies of CEU’s obtained.
3. Every submission must be Cardiology related.
4. Job requirements may not necessarily meet the criteria for CEU’s. i.e. code blue review, hardware/software instructions
5. Formal classes must be from an accredited program and must fall under the NOCP guidelines.
6. Preceptors must be for a Cardiology Technology program or CLXT/MLA and from an accredited program recognized by the CSCT
7. Members will receive 1 CEU for every 30-minute video cited, or 2 CEU’s if there is a summary written about it.
8. Members must submit the learning objective and instructor for any lectures or in-services. If it falls under “entry level to practice” according to the NOCP guidelines, members will only receive 2 CEU’s per triennium for these activities.
9. CEU’s for teaching will not be granted if you are being paid as an instructor from an educational institution. They must be accumulated for teaching during working hours or volunteering after hours.
Clinical Implications of Echo-Derived Hemodynamic Findings After TAVR
Duration: 30 minutes
CEU Value: 1
CSCT CEU STANDARDS SECTION: 2F
Description:
Program Description
The number of patients who have undergone transcatheter aortic valve replacement (TAVR) has risen steeply in recent years. Favorable outcomes data supporting TAVR as an alternative to surgical aortic valve replacement (SAVR) have coincided with a substantial expansion of the volume of aortic valve replacements, with a shift from SAVR to TAVR as the more common procedure. As the population of patients who have undergone TAVR grows, clinicians are increasingly challenged to provide these patients with appropriate monitoring, particularly in relation to the potential for structural valve deterioration. Echocardiography is the mainstay for post-TAVR hemodynamic monitoring—but as a noted expert explains in this video, there are some important caveats about how to interpret echo-derived measurements in this population, particularly that an increased transvalvular pressure gradient does not always indicate impending valve failure.
The Future of TAVR: Assessing the Rapidly Evolving Role of Transcatheter Aortic Valve Replacement
Duration: 75 minutes
CEU Value: 1.5
CSCT CEU STANDARDS SECTION: 2F
Description:
Program Description
Thanks to a robust and rapidly growing evidence base, including shorter hospital stays and faster recovery periods, transcatheter aortic valve replacement (TAVR) is now the standard of care for the majority of patients with aortic stenosis (AS), including patients with low risk for surgical aortic valve replacement (SAVR). Nevertheless, many questions remain about factors that affect ventricular function recovery and long-term outcomes following TAVR.
In this video roundtable, 5 nationally known experts discuss approaches to patient selection, post-TAVR hemodynamic assessments and their prognostic implications, including the impact of patient-prosthesis mismatch and paravalvular leak on long-term outcomes, as well as implementing the optimal antithrombotic regimen following TAVR.
TAVR: Optimizing Resource Utilization in the Management of Patients With Aortic Stenosis
Duration: 60 minutes
CEU Value: 1
CSCT CEU STANDARDS SECTION: 2F
Description:
Program Description
Severe symptomatic aortic stenosis demands urgent care. But which approach is best for a given patient? In this video webinar, 3 experts explore the clinical pathways and health economics of transcatheter aortic valve replacement (TAVR) in comparison to traditional open surgical aortic valve replacement (SAVR), including the impact of treatment delays in this vulnerable population. As you will note, as more and more centers have started offering TAVR, providers are achieving excellent clinical outcomes and cost efficacy due to clinical efficiencies and device iterations. Unfortunately, the COVID-19 pandemic has shown us the urgency of treating severe symptomatic aortic stenosis. Many patients have been sitting on the sidelines delaying treatment—and the data show that delayed treatment is associated with compromised outcomes.
TAVR Today: Real-World Challenges; Real-World Opportunities—An Expert Perspective Roundtable on New and Emerging Data on TAVR
Duration: 60 minutes
CEU Value: 1
CSCT CEU STANDARDS SECTION: 2F
Link: TAVR Today: Real-World Challenges; Real-World Opportunities (mycme.com)
Description:
Program Description
Aortic stenosis is relatively common in older adults. Once symptoms develop, the condition is rapidly fatal without treatment. Effective therapy historically has involved surgical aortic valve replacement (SAVR), an intervention for which many patients were not candidates due to surgical risk. Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of aortic stenosis, demonstrating equivalence or benefit compared with surgery for an ever-growing range of patients. It is now guideline-recommended for patients at prohibitive and high surgical risk, is a recommended option in those at intermediate risk, and has demonstrated benefit in those at low surgical risk. Despite these advances, untreated aortic stenosis is common and many clinicians remain unaware of the benefits of TAVR and how to identify candidates for TAVR and SAVR. This roundtable features a leading cardiac surgeon and a noted interventional cardiologist with a prominent clinical cardiologist reviewing the latest data about TAVR and SAVR along with when to recommend each procedure.
HIV with Comorbid Conditions: Managing the Metabolic Syndrome, Diabetes and Cardiovascular Disease in Older Patients Living with HIV
Duration: 75 minutes
CEU Value: 1.5
CSCT CEU STANDARDS SECTION: 2F
Description:
Program Description
Experts in the management of patients living with HIV discuss current significant issues including the effect of aging and associated HIV-related comorbidities, the increasingly important role of primary care providers in prevention and risk management, and the effect of COVID-19 on HIV management. Emphasis will be placed on the metabolic syndrome, its components, and its effect on HIV management. Key components of the metabolic syndrome in HIV, including abdominal obesity, dyslipidemia, insulin resistance, and hypertension will be reviewed separately, and the potential role of antiretroviral therapy on the metabolic syndrome will be considered. The relationship between HIV, diabetes, and cardiovascular disease then will be examined in detail.
Navigating the Evolving Paradigm in Heart Failure: The Emerging Impact of SGLT2 Inhibition
Duration: 75 minutes
CEU Value: 1.5
CSCT CEU STANDARDS SECTION: 2F
Description:
Program Description
This enduring activity evaluates the pathophysiologic mechanisms linking type 2 diabetes (T2D) and heart failure (HF), and explores the early evolution of SGLT2 inhibition in the era of cardiovascular outcomes trials (CVOTs). Expert faculty examine new and emerging CVOT data for SGLT2 inhibitors in HFrEF and HFpEF, including recent approvals and updated guideline recommendations, and offer insights into how these agents are shifting the HF treatment paradigm and broadening horizons for both diabetic and nondiabetic patients. To reinforce these teaching points within the context of an integrated treatment approach, participants will be engaged in a case-based discussion focused on the implementation of SGLT2 inhibitors in HF patients predicated on evolving CVOT data, in tandem with identification of key characteristics of an effective, integrated approach to HF management.
Cardio Obstetrics Around The World
Duration: 120 minutes
CEU Value: 2
CSCT CEU STANDARDS SECTION: 2F
Link: Cardio Obstetrics Around The World | myCME
Description:
Program Description
Welcome to "Cardio Obstetrics Around the World." Your journey will start out in the Western Hemisphere with an Introduction to Cardio Obstetrics, described from the MFM Perspective in Irvine, California and the Cardiology Perspective in Toronto, Canada. These Keynote Speakers, Dr. Hameed and Dr. Silversides respectively will prepare you for the three cases to follow presented from Kigali, Rwanda; Milano, Italia; Meridien, Colombia. Now fasten your seatbelts and sit back enjoy.
The high-risk birthing profile in the USA currently includes the cardiac pregnant patient, at highest risk for Maternal Mortality. The alarming trend of rising cardiovascular related maternal mortality should serve as an impetus for obstetricians and cardiologists to join hands and take up the call to action in a coordinated effort. Cardiovascular screening, patient education and multidisciplinary team planning is an essential triad to eliminate preventable maternal death. We aim to advocate this triad approach to the cardiac pregnant patient.
Keeping the Beat: Screening and Management of High-Risk Patients with Non-Valvular Atrial Fibrillation
Duration: 90 minutes
CEU Value: 1.5
CSCT CEU STANDARDS SECTION: 2F
Link: Keeping the Beat: Screening and Management of Non-Valvular Atrial Fibrulation | myCME
Description:
Program Description
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, projected to affect 12 million Americans by 2030. However, a significant number of AF cases, particularly non-valvular atrial fibrillation (NVAF) remain undiagnosed, putting patients at risk for severe cardiovascular (CV) complications, including increased risk of stroke. It is imperative that clinicians identify the symptomatology of AF and effectively diagnose NVAF, as these complications can potentially be avoided by increased screening and guideline-directed anticoagulation treatment. Unfortunately, despite the fact that both opportunistic and systematic screening have been shown to be effective in detecting NVAF, clinicians often lack knowledge of the available tools and strategies for implementing it, particularly in primary care settings.
This CME Outfitters Live and OnDemand webcast will feature expert faculty addressing the impact of undiagnosed NVAF, the benefit and use of screening tools for early detection, best practices for optimizing screening, implementing oral anticoagulant therapy for stroke prevention, and the use of digital health technologies, with a goal of fostering collaborative care and optimizing patient outcomes.
Understanding the Importance of Screening CTD Patients for PAH
Duration: 30 minutes
CEU Value: 1
CSCT CEU STANDARDS SECTION: 2F
Link: https://www.mycme.com/courses/understanding-the-importance-of-screening-ctd-patients-for-pah-7268
Description:
Program Description
In this video-based activity, Dr. Dinesh Khanna shares the importance of screening patients with connective tissue disease for pulmonary arterial hypertension to facilitate earlier diagnosis and improve patient outcomes. Dr. Khanna discusses the impact of delayed diagnosis, screening protocols, barriers to physician adherence, and the importance of a multidisciplinary team. A patient case offers real-world insight and key takeaways for application to clinical practice.